🚀 Calcium Score & CCTA: Key Highlights from the 2025 AHA Scientific Statement (DOI: 10.1161/CIR.0000000000001394) Non-obstructive CAD in Chest Pain Patients 🧊 1. CAC = Atherosclerotic Burden, Not Just a Number CAC is one of the strongest predictors of future ASCVD risk—better

🚨 AHA 2025 | CORALreef Lipids Trial A true game changer in lipid management. 💊 Enliciditide (MK-0616) — the first oral PCSK9 inhibitor — achieved a 57% LDL-C reduction at week 24 and −50% sustained at week 52 vs placebo (p<0.001). 👥 Phase 3 trial, 2,912 patients with

Trial data from 12k patients published *today* add to HUGE body body of data that this is deadly wrong LDL is a causal, prognostic, therapeutic target for atherosclerotic cardiovascular disease Drugs targeting at least 4 different molecular pathways to lower LDL also reduce

I wouldn’t exactly call myself a black belt in beta-blockers, but with all this talk of superiority, "non-superiority," and "non-non-inferiority," it’s really enough to get confused. If I interpret correctly the avalanche of trials from the past year, accompanied by the

The Drug-Coated Balloon Academic Research Consortium presents a global consensus to standardise clinical trials on DCBs in obstructive CAD. It defines study designs, endpoints, imaging methods, follow-up, and introduces the concept of “blended therapy.” @FezziSimone ;

Perspectives on Artificial Intelligence in Medical... : Journal of Cardiovascular Pharmacology https://t.co/embivanu3u #AI #cardiology #cardiovascular

This study indicates that photon-counting detector computed tomography (PCD-CT) provides high diagnostic accuracy for detecting in-stent restenosis in patients with prior coronary stents. This suggests that PCD-CT may be reliably used to evaluate suspected obstructive coronary

#cardiology #cardiovascular #cardioX #cardiotwitter

I have translated into slides the topics and references used by the 2025 Guidelines Task Force on valvular heart disease to justify the recommendation for TAVI in patients aged 70 years or older. Their key argument is a certain degree of pragmatism — they consider age as a

We authored this state-of-the-art review, now published in JACC, to provide an updated, comprehensive overview of post–myocardial infarction inflammatory mechanisms and to critically evaluate the emerging clinical evidence on anti-inflammatory therapies for secondary

Yet another trial in STEMI with multivessel disease: in OPTION-STEMI, immediate complete revascularization was not shown to be non-inferior to staged complete revascularization during the index admission, looking at death, non-fatal MI, or unplanned revascularization at 1 year.

Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes: @NEJM 🥸 The slow decline of aspirin: #ESCCongress2025 😱 Here is the summary of the NEO-MINDSET Trial 👇👇👇

IDEAL-LM 5-year results: In patients undergoing PCI for left main disease, biodegradable-polymer DES + 4mo DAPT showed no advantage over durable-polymer DES + 12mo DAPT. MACE, MI, TVR, and ST rates were similar. #EAPCI #LMPCI #DES #DAPT https://t.co/DIl6lav6wg

The Pullback Pressure Gradient: A Physiologic Index to Differentiate Focal From Diffuse CAD - State-of-the art collaborative review ( https://t.co/fA0QmIpmkk) between @CCAD_MHIF & @CoreAalst on PPG is now available in the latest issue of JACC Advances @PedroEPCarvalho

This is the new #PPG Pullback Pressure Gradient - a new physiology-based paradigm in coronary decision-making High PPG = focal CAD / Low PPG = diffuse CAD We hope PPG helps us become better interventional cardiologists🙏 @PCRonline @AbbottCardio @coroventis @TCTMD @CoreAalst

We are entering a new era in coronary revascularization—where predicting PCI success becomes central to clinical decision-making. Our latest view on how this shift is reshaping the field https://t.co/n0nO3mbcoE @CardioAalst @PCRonline @TCTMD

Harvard has set an example for other higher-ed institutions – rejecting an unlawful and ham-handed attempt to stifle academic freedom, while taking concrete steps to make sure all students at Harvard can benefit from an environment of intellectual inquiry, rigorous debate and

#ODYSSEY: LDL-C, Lp(a), and hs-CRP provide prediction of MACE risk after ACS. For hs-CRP and lipoprotein(a), risk starts at low levels. LDL-C and hs-CRP are predictors of death, Lp(a) not. @gabrielsteg @SABOURETCardio @DLBHATTMD @cpgale3 @mmamas1973 @pash22 @CircAHA #CardioX

#cardiology #cardiotwitter #cardioX #ACC25 @CNIC_CARDIO

Late-breaker at #ACC2025: Dr. Joo-Yong Hahn presented the SMART-CHOICE 3 trial, showing superior efficacy and comparable safety of clopidogrel as long-term maintenance monotherapy in high-risk pts compared to aspirin. Slides here: https://t.co/XLZy7c4e6j